The U.S. initial public offering market continued to broaden this week as companies from consumer retail, biotechnology, and cloud infrastructure successfully entered the public markets, providing fresh evidence that investor appetite is extending beyond the technology sector.

The week’s calendar featured four notable listings across multiple industries, raising hopes that the IPO window is becoming more accessible for companies with differentiated business models and attractive valuations.

While market conditions remain selective, successful offerings from restaurant chain Jersey Mike’s, apparel brand Reformation, biotechnology company Apnimed, and direct-listed data center operator Ionic Digital suggest investors are increasingly willing to support a wider range of issuers.

Jersey Mike’s Completes Largest Restaurant IPO in Over a Decade

The week’s headline offering came from Jersey Mike’s Subs (NYSE: JMKE), which raised $1 billion in the largest restaurant IPO since 2011.

Backed by Blackstone, the sandwich chain priced its offering at the midpoint of its expected range, achieving an approximately $8.9 billion valuation. Initial trading proved cautious, with shares briefly falling below their offering price before recovering to finish the week roughly flat.

Despite the modest trading debut, the successful completion of the offering represents an important milestone for consumer IPOs, demonstrating that sizable restaurant listings remain achievable even amid a challenging environment for publicly traded restaurant stocks.

Reformation Delivers Positive Consumer Debut

Women’s apparel company Reformation (NYSE: REF) also entered public markets, pricing its IPO at the low end of its expected range before delivering an approximately 8% gain following its debut.

The successful listing marks one of the first notable direct-to-consumer fashion IPOs in several years. Although investors required more conservative pricing, Reformation’s positive aftermarket performance suggests demand remains healthy for consumer brands that demonstrate recognizable products and scalable growth opportunities.

Together, the Jersey Mike’s and Reformation offerings provide encouraging signals for additional consumer companies considering public listings later this year.

Biotech Momentum Continues with Strong Apnimed Debut

Biotechnology remained one of the strongest-performing IPO sectors.

Sleep apnea drug developer Apnimed (Nasdaq: APMD) increased the size of its offering, priced shares at the top of its expected range, and delivered an impressive 56% first-week gain.

The strong reception reflects continued investor interest in innovative healthcare companies, particularly those addressing significant unmet medical needs. Recent biotech IPOs have consistently outperformed broader new issue markets, encouraging additional life sciences companies to advance their own public offerings.

Ionic Digital Completes Largest Direct Listing Since 2021

Artificial intelligence infrastructure and digital asset company Ionic Digital (Nasdaq: IOND) successfully completed the largest direct listing since 2021 despite ongoing volatility surrounding AI-related equities.

The company finished the week with an estimated $3.1 billion market capitalization, demonstrating that investor demand continues to exist for differentiated infrastructure businesses even as broader AI-related stocks experience periods of weakness.

The listing also highlights continued investor interest in companies benefiting from the growing demand for high-performance computing and data center infrastructure.

IPO Pipeline Remains Active

The primary market remains busy heading into next week.

Several biotechnology companies, including BRVE, Attovia Therapeutics (ATTO), and Vogenx (VOGX), are expected to launch offerings, alongside bank issuer RCBC, further expanding sector diversity within the IPO calendar.

Market participants will also closely monitor SpaceX, which is scheduled to report earnings for the first time as a public company. Investors are expected to pay particular attention to the company’s first major lock-up expiration, during which approximately 911 million shares will become eligible for trading, more than doubling the available public float.

How the market absorbs this substantial increase in tradable shares could influence sentiment toward future large-cap IPOs.

Broader IPO Market Faces Mixed Performance

Despite encouraging activity in the primary market, newly public companies continued facing broader macroeconomic headwinds.

The IPO Index declined 0.7% during the week, underperforming the S&P 500, which gained 1.0%. Investor sentiment remained affected by continued weakness across certain AI-related stocks and the Federal Reserve’s decision to leave interest rates unchanged while signaling that further policy tightening remains possible.

Among recent issuers, defense company Arxis surged 28.1% following stronger-than-expected earnings and higher guidance, while healthcare services provider BrightSpring Health Services fell 18.1%, as valuation concerns outweighed otherwise solid quarterly results.

Outlook

This week’s diverse slate of IPOs suggests the U.S. new issue market is gradually broadening beyond its recent concentration in technology and biotechnology. While investors continue demanding disciplined valuations and strong business fundamentals, successful offerings across restaurants, consumer retail, healthcare, and infrastructure indicate improving confidence in the primary market. Upcoming biotech listings, financial sector offerings, and the closely watched SpaceX earnings and lock-up expiration will provide additional insight into whether this expanding IPO window can maintain its momentum through the remainder of the year.